Cassava Sciences Inc (PX91 F) stock market data APIs
€1.7537
0(0%)
as of January 20, 2026
Try our APIs with
free plan!
Cassava Sciences Inc Financial Data Overview
Price chart is built with
Anychart
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
Prev. Close
1.7537
Open
1.7537
High
1.7537
Low
1.7537
52 wk Range
1.0295-3.902
Market Cap
87 886 K
Shares Outstanding
48 308 K
EPS
-0.13
Beta
-1.006
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cassava Sciences Inc data using free add-ons & libraries
Get Cassava Sciences Inc Fundamental Data
Cassava Sciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -69 296 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-03
- EPS/Forecast: -0.13
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cassava Sciences Inc News
New
Cassava Sciences Stock Continues Showing Rising Relative Strength
On Tuesday, Cassava Sciences reached an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 90-plus percentile with an improvement to 92, up from 87 the previous trad...
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
Cassava Sciences, Inc. Shareholders of Record Received Warrants to Purchase Shares of Common Stock Warrants Trade on Nasdaq Under the Ticker “SAVAW” Warrant Holders Who Choose to Exercise During...
Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the sh...
Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days
Cassava Sciences saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an upgrade from 79 to 88. The company earns the No. 172 rank among its peers in the Medical-Biomed/Biotech industry group. Continue reading
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
